Literature DB >> 9430248

An HIV type 2 DNA vaccine induces cross-reactive immune responses against HIV type 2 and SIV.

M G Agadjanyan1, N N Trivedi, S Kudchodkar, M Bennett, W Levine, A Lin, J Boyer, D Levy, K E Ugen, J J Kim, D B Weiner.   

Abstract

We have previously reported on the generation of specific functional immune responses after inoculation of animals with expression vectors encoding HIV-1 genes. This article provides the details of the first application of this new technology to induce immune responses against HIV-2. This virus is molecularly and serologically distinct from HIV-1 and is in fact more closely related to the simian immunodeficiency virus (SIV). Anti-HIV-2 and SIV antibodies were induced in mice of three different haplotypes following a single intramuscular inoculation with an HIV-2/ROD envelope glycoprotein expression vector (pcEnv-2). Boosting of animals with pcEnv-2 induced both anti-HIV-2 neutralizing antibodies and T cell-proliferative responses against HIV-2 and SIVmac proteins. We compared the humoral and cellular immune responses of mice injected with pcEnv-2 and then boosted with either the homologous DNA construct or a recombinant Env protein. Animals boosted with pcEnv-2 generated B and T cell immune responses as strong as those of mice boosted with recombinant gp140 protein in adjuvant. Finally, cellular immune responses were significantly increased with the coadministration of pcEnv-2 and a plasmid expressing interleukin 12. We therefore conclude that DNA plasmid inoculation induces cross-reactive anti-HIV-2 and anti-SIVmac immune responses in mice. This technology should be further investigated as a potential vaccine component for this human pathogen.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9430248     DOI: 10.1089/aid.1997.13.1561

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  6 in total

1.  DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques.

Authors:  S Cherpelis; I Shrivastava; A Gettie; X Jin; D D Ho; S W Barnett; L Stamatatos
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

2.  Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid.

Authors:  David H Cribbs; Anahit Ghochikyan; Vitaly Vasilevko; Mike Tran; Irina Petrushina; Nadya Sadzikava; Davit Babikyan; Patrick Kesslak; Thomas Kieber-Emmons; Carl W Cotman; Michael G Agadjanyan
Journal:  Int Immunol       Date:  2003-04       Impact factor: 4.823

3.  DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice.

Authors:  H Davtyan; M Mkrtichyan; N Movsesyan; I Petrushina; G Mamikonyan; D H Cribbs; M G Agadjanyan; A Ghochikyan
Journal:  Gene Ther       Date:  2009-10-29       Impact factor: 5.250

4.  Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene.

Authors:  Anahit Ghochikyan; Vitaly Vasilevko; Irina Petrushina; Nina Movsesyan; Davit Babikyan; Wenqiang Tian; Nadya Sadzikava; Ted M Ross; Elizabeth Head; David H Cribbs; Michael G Agadjanyan
Journal:  Eur J Immunol       Date:  2003-12       Impact factor: 5.532

5.  Immunostimulant patches containing Escherichia coli LT enhance immune responses to DNA- and recombinant protein-based Alzheimer's disease vaccines.

Authors:  Hayk Davtyan; Anahit Ghochikyan; Armine Hovakimyan; Irina Petrushina; Jianmei Yu; David Flyer; Peter Juul Madsen; Lars Ostergaard Pedersen; David H Cribbs; Michael G Agadjanyan
Journal:  J Neuroimmunol       Date:  2014-01-15       Impact factor: 3.478

6.  Vaccination of mice using the West Nile virus E-protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects mice against a lethal challenge.

Authors:  Marina De Filette; Silke Soehle; Sebastian Ulbert; Justin Richner; Michael S Diamond; Alessandro Sinigaglia; Luisa Barzon; Stefan Roels; Julianna Lisziewicz; Orsolya Lorincz; Niek N Sanders
Journal:  PLoS One       Date:  2014-02-04       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.